Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

European Commission approves Stivarga tablets for treatment of patients with mCRC

European Commission approves Stivarga tablets for treatment of patients with mCRC

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Personalized rectal cancer therapy shows promise

Personalized rectal cancer therapy shows promise

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Study finds PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer

Usefulness of liver biopsy for CALI preoperative assessment questioned

Usefulness of liver biopsy for CALI preoperative assessment questioned

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

FDA approves KRAS gene mutation test for colorectal cancer

FDA approves KRAS gene mutation test for colorectal cancer

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies